In This Article:
Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains.